FDA won't hold companies responsible for independent user content on their social media properties

U.S. pharmaceutical companies may have gotten off easy compared to other areas of the world, said Peter Pitts, president of the Center for Medicine in the Public Interest and a former associate commissioner at the FDA.

The European Court of Justice recently ruled that online remarks about drugs posted by a third party on the manufacturer's Web property could constitute advertising, even though the post's author has no connection with the product's manufacturer or marketer.

“That's carte blanche for an almost complete gag order on anyone who wants to discuss anything to do with medicines,” Pitts said.
Sign Up for Our Email Newsletter

RECENT NEWS

New JCI Viewpoint: FDA Must Rethink How It Evaluates Precision Medicines for Rare Diseases

New JCI Viewpoint: FDA Must Rethink How It Evaluates Precision Medicines for Rare Diseases

Authors argue that rare disease innovation requires learning more from fewer patients—not enrolling more patients...  Read more

Troubling Trends: Systemic Practices in Texas' Non-Profit Hospitals That Inflate Health Care Costs

Troubling Trends: Systemic Practices in Texas' Non-Profit Hospitals That Inflate Health Care Costs

Texas has an opportunity to lead rather than react. Better measurement would strengthen public confidence without diminis...  Read more

PROTECTING THE U.S. PHARMACEUTICAL SUPPLY CHAIN: A PATH FORWARD

PROTECTING THE U.S. PHARMACEUTICAL SUPPLY CHAIN: A PATH FORWARD

How proactive FDA policies can help strengthen the American pharmaceutical supply chain of essential medicines, create jo...  Read more

DRUGWONKS BLOG